The dynamics of death in prostate cancer

American Journal of Clinical Pathology

Volumn 137, Issue 6, 2012, Pages 957-962

  Vollmer, Robin T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hazard function; Histology; Prostate cancer; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; HISTOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TUMOR VOLUME; BLOOD; CANCER GRADING; CANCER REGISTRY; FOLLOW UP; INCIDENCE; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL;

FOLLOW-UP STUDIES; HISTOLOGY; HUMANS; INCIDENCE; MALE; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 84863766451     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPJK9V9LUMUETV     Document Type: Article

References (27)

1. Ablin RJ, Soanes WA, Bronson P, et al. Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970;22:573-574.
2. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159-163. (Pubitemid 10132507)
3. Papsidero LD, Wang MC, Valenzuela LA, et al. A prostate antigen in the sera of prostatic cancer patients. Cancer Res. 1980;40:2428-2432. (Pubitemid 10082262)
4. Killian CS, Yang N, Emrich LJ, et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res. 1985;45:886-891. (Pubitemid 15161096)
5. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916. (Pubitemid 17147932)
6. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142:1011-1017. (Pubitemid 19250754)
7. Andriole GL. Serum prostate specific antigen: the most useful tumor marker. J Clin Oncol. 1992;10:1205-1207.
8. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290. (Pubitemid 24121936)
9. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990. (Pubitemid 34814727)
10. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26:233-239.
11. Kronz JD, Milord R, Wilentz R, et al. Lesions missed on prostate biopsies by pathologists [abstract]. Mod Pathol. 2001;14:114A.
12. Griffiths RC, Epstein JI. Review of prostate needle biopsies by an expert [abstract]. Mod Pathol. 2001;14:110A.
13. Smith DS, Carvalhal GF, Mager DE, et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 1998;160:1734-1738. (Pubitemid 128746747)
14. Lodding P, Aus G, Bergdahl S, et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/mL prostate specific antigen. J Urol. 1998;159:899-903. (Pubitemid 28106553)
15. Catalona WJ, Ramos CG, Carvalhal GF, et al. Lowering the PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55:791-795. (Pubitemid 30330772)
16. Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335-342. (Pubitemid 36886239)
17. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994;47:3-21. (Pubitemid 24034286)
18. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878. (Pubitemid 36833878)
19. Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics. 2004;5:603-613. (Pubitemid 41180208)
20. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-1329.
21. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
22. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
23. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605-613.
24. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol. 1985;3:1418-1431. (Pubitemid 15244940)
25. Yakovlev AY, Tsodikov AD, Boucher K, et al. The shape of the hazard function in breast cancer: curability of disease revisited. Cancer. 1999;85:1789-1798. (Pubitemid 29169681)
26. Vollmer RT. Tumor length in prostate cancer. Am J Clin Pathol. 2009;131:86-91.
27. Harrell FE Jr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001:392-398.